Theorem Clinical Research has announced the formation of a strategic alliance with Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration.
Theorem Clinical Research
has announced the formation of a strategic alliance with
Charles River Laboratories
that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity and immunology to support clinical trials.
“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said
Dr. Marc Hoffman
, Theorem senior vice president and general manager of
biopharmaceutical development
.
Charles River’s
high-quality research models
, preclinical testing capabilities and clinical support services are backed by a comprehensive bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped with the latest instrumentation to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis. The variety of advanced equipment ensures the capacity to meet critical deadlines.
“We are pleased to partner with a world-class clinical trials organization like Theorem Clinical Research. Sponsors will benefit from the experience of both organizations. The alliance will offer a seamless transition from preclinical testing into the clinical arena,” said Alan Bartlett, executive director of laboratory services,
Charles River Laboratories
.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.